Client results
IMUGENE LIMITED
A$46 MILLION CAPITAL RAISE
McCullough Robertson’s Equity Capital Markets and Life Sciences team has assisted clinical stage immuno-oncology company, Imugene Limited (Imugene) in securing a capital injection of up to A$46 million to support its clinical trial pipeline via the issue of convertible notes and warrants to CVI Investments Inc.
The issuance, which involves A$20 million of convertible notes and up to a further A$26 million through the issue of unlisted warrants, provides Imugene with pivotal up-front funding, while avoiding the traditional drawbacks of other convertible notes.
The capital raised will be used for Imugene’s ongoing clinical trials for its azer-cel, onCARlytics, and VAXINIA programs for the treatment of solid tumours and blood cancers.
The McCullough Robertson team, led by Partner Reece Walker, has proudly supported Imugene since 2013.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $77.89M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.3¢ | $1.990M | 7.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 209631 | 9 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |